Thymalin
From PeptidePlaza, the free peptide reference · Entry #044 · Anti-Aging · Hand-curated entry · Editorial standards
Thymalin (also known as Thymalinum, Thymus peptide complex, Tималин) is a anti-aging research peptide. A Soviet-era thymic extract, not a single molecule. The centrepiece of the Khavinson bioregulator programme — and of a 6-to-12-year follow-up study whose mortality claims have never been replicated.
Thymalin is a complex of low-molecular-weight polypeptides extracted from calf thymus, developed in the Soviet Union in the 1970s by Vladimir Khavinson and colleagues as part of a broader "peptide bioregulator" programme that also produced Epitalon (pineal) and Cortexin (cortical). It is not a defined single peptide: it is a fractionated extract, which makes batch-to-batch consistency, characterisation and mechanistic attribution fundamentally difficult. The stated mechanism is restoration of thymic function — promoting T-lymphocyte differentiation and maturation, normalising the CD4/CD8 ratio, and rebalancing cytokine profiles in immunosuppressed or elderly subjects. It remains registered as a pharmaceutical in Russia and some former Soviet states, where it has been used adjunctively for infections, post-surgical immune support and radiation injury. The most cited claim — a long-term follow-up in elderly subjects reporting reduced mortality with repeated thymalin courses over 6 to 12 years — comes from the Khavinson group itself, was not blinded or independently replicated, and is not accepted as evidence outside that literature. Western peer-reviewed data is thin, and most of the primary literature is in Russian.
1 Mechanism of action
Reported to promote T-lymphocyte differentiation and maturation, restore CD4/CD8 balance, and modulate cytokine production toward normalised immune function. The bioregulator hypothesis proposes that short peptides interact with DNA regions to influence tissue-specific gene expression, but this mechanism is not established by independent research.
Primary targets: Not characterised — extract with multiple active fractions
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Reported benefits
- Reported restoration of T-cell differentiation and CD4/CD8 balance
- Registered pharmaceutical in Russia with decades of clinical use in immune support
- Studied adjunctively in infection, post-surgical recovery and radiation injury
- Reported normalisation of cytokine profiles in immunosuppressed subjects
- Long observational follow-up data in elderly cohorts (unreplicated)
2.2 Side effects
- Allergic and hypersensitivity reactions (bovine-derived material)
- Injection site pain and erythema
- Theoretical autoimmune activation in predisposed individuals
- Unknown contaminant profile inherent to animal tissue extracts
3 Chemical and physical properties
| Purity (typical) | Extract — purity not definable as for a single peptide |
|---|---|
| Half-life | Not characterised (extract, not a defined molecule) |
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
| Receptors / targets | Not characterised — extract with multiple active fractions |
3.1 Amino acid sequence
Polypeptide complex extracted from calf thymus; not a single defined sequence
4 Research dosages
Russian clinical convention: 10 mg IM daily for 5–10 days per course, with courses repeated at intervals. No Western validated protocol.
5 Research studies (6)
- Transient hepatic reconstitution of trophic factors enhances aged immunity.
Nature (2026) · PreclinicalAgeing erodes human immunity, in part by reshaping the T cell repertoire, leading to increased vulnerability to infection, malignancy and vaccine failure1-3. - Aging and Thymosin Alpha-1.
International journal of molecular sciences (2025) · ReviewAging is characterized by immune decline, mainly due to thymic involution-the age-related shrinkage of the thymus gland. - Recirculating regulatory T cells mediate thymic regeneration through amphiregulin following damage.
Immunity (2025) · PreclinicalThymic injury associated with disease or cancer treatment reduces T cell production and makes patients more vulnerable to infections and cancers. - Enhanced paracrine action of FGF21 in stromal cells delays thymic aging.
Nature aging (2025) · PreclinicalAge-related thymic involution precedes aging of all other organs in vertebrates and initiates the process of declining T cell diversity, which leads to eventual immune dysfunction. - RANKL treatment restores thymic function and improves T cell-mediated immune responses in aged mice.
Science translational medicine (2024) · PreclinicalAge-related thymic involution, leading to reduced T cell production, is one of the major causes of immunosenescence. - Age-related thymic involution: Mechanisms and functional impact.
Aging cell (2022) · ReviewThe thymus is the primary immune organ responsible for generating self-tolerant and immunocompetent T cells.
6 Safety and risk profile
6.1 Regulatory status
Thymalin is currently classified as Not approved. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
Safety score: 58/100 — moderate concern. Derived from clinical data volume, known risks and regulatory status.
6.2 Contraindications
Conditions and populations in which use is contraindicated:
- Known hypersensitivity to bovine proteins
- Active autoimmune disease
- Pregnancy or lactation
- Immunosuppressive therapy where immune stimulation is undesirable (e.g. transplant)
6.3 Drug interactions
| Drug or class | Interaction | Risk |
|---|---|---|
| Immunosuppressants | Immunostimulatory action directly opposes the therapeutic goal of immunosuppression; relevant in transplant and autoimmune settings. | High |
| Vaccines | May alter vaccine response; timing should be considered in protocols. | Low |
| Other thymic peptides (Thymosin Alpha-1) | Overlapping mechanisms; no data on combined use. | Low |
6.4 Long-term risks
- Unknown — no modern long-term safety monitoring outside the originating research group
- Repeated exposure to bovine-derived material raises sensitisation risk
- Chronic immune modulation of uncharacterised direction
6.5 Research best practices
- Store lyophilised at 2–8 °C, protected from light
- Reconstitute with sterile saline or water for injection immediately before use
- Demand full source and process documentation — extract quality is entirely process-dependent
- Treat published longevity claims as unreplicated preliminary data
7 Frequently asked questions
- Is thymalin the same as Thymosin Alpha-1?
- No. Thymosin Alpha-1 is a defined 28-amino-acid synthetic peptide with dozens of registered clinical trials. Thymalin is an undefined polypeptide extract from calf thymus. They come from the same tissue and are described as doing similar things, but only one is a characterised molecule with a modern evidence base.
- What about the claimed mortality reduction in the elderly?
- That result comes from the Khavinson group's own long-term follow-up work and has not been independently replicated or reproduced under blinded conditions. It is widely cited in bioregulator marketing and should be treated as a preliminary, unreplicated claim rather than established evidence.
- Why is characterisation such a problem here?
- Because a tissue extract has no single molecular identity. Composition varies with source material and process, which makes purity testing, dose standardisation, mechanistic attribution and independent replication all substantially harder than for a synthetic peptide.
8 References
- Transient hepatic reconstitution of trophic factors enhances aged immunity. PubMed (2026). Friedrich MJ, et al.. View source
- Aging and Thymosin Alpha-1. PubMed (2025). Simonova MA, et al.. View source
- Recirculating regulatory T cells mediate thymic regeneration through amphiregulin following damage. PubMed (2025). Lemarquis AL, et al.. View source
- Enhanced paracrine action of FGF21 in stromal cells delays thymic aging. PubMed (2025). Youm YH, et al.. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Thymalin.
Shares active and mechanism pharmacology
A low-molecular-weight peptide fraction from porcine brain tissue, used across Europe and Asia for stroke and dementia for decades. Decades of trials, and the Cochrane verdict is still not favourable.
Shares balance and toward pharmacology
The first drug that builds bone rather than merely slowing its loss — and it works only because it is given as a daily pulse. Continuous exposure to the same peptide destroys bone instead.
Shares expression and immune pharmacology
A synthetic analog of the endogenous tetrapeptide Tuftsin. Developed by the Russian Institute of Molecular Genetics. Studied for anxiolytic, nootropic, and immunomodulatory effects without sedation or dependence.
Shares gene and expression pharmacology
A synthetic tetrapeptide derived from the pineal gland peptide Epithalamin. Studied extensively by Vladimir Khavinson for telomerase activation, circadian regulation, and life extension in animal models.
Shares maturation and immune pharmacology
A 28-amino acid thymic peptide that modulates T-cell function and cytokine balance. Studied clinically for chronic hepatitis B, sepsis, and vaccine response augmentation for over 30 years.
Shares cytokine and gene pharmacology
A 28-amino-acid neuropeptide with potent anti-inflammatory and immunomodulatory actions. Being studied for autoimmune diseases, type 2 diabetes, and antiviral applications.